306 related articles for article (PubMed ID: 37662925)
21. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
22. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
23. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Saturno G; Lopes F; Niculescu-Duvaz I; Niculescu-Duvaz D; Zambon A; Davies L; Johnson L; Preece N; Lee R; Viros A; Holovanchuk D; Pedersen M; McLeary R; Lorigan P; Dhomen N; Fisher C; Banerji U; Dean E; Krebs MG; Gore M; Larkin J; Marais R; Springer C
Ann Oncol; 2021 Feb; 32(2):269-278. PubMed ID: 33130216
[TBL] [Abstract][Full Text] [Related]
24. Targeting KRAS in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract][Full Text] [Related]
25. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
Shu CL; Liu YL
Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
27. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
28. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
29. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
30. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
31. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
32. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
33. Targeting Mutated KRAS Genes to Treat Solid Tumours.
Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
[TBL] [Abstract][Full Text] [Related]
34. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for
Köhler J; Jänne PA
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809660
[TBL] [Abstract][Full Text] [Related]
35. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
36. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
Srisongkram T; Weerapreeyakul N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
[TBL] [Abstract][Full Text] [Related]
37. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
38. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
Chen W; Li L; Cheng S; Yu J
Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
[TBL] [Abstract][Full Text] [Related]
39. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
[TBL] [Abstract][Full Text] [Related]
40. The promise and peril of KRAS G12C inhibitors.
Moore AR; Malek S
Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
